NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Get Free Report)’s share price was down 0.8% during mid-day trading on Monday . The company traded as low as $1.23 and last traded at $1.24. Approximately 407,132 shares traded hands during trading, an increase of 101% from the average daily volume of 202,154 shares. The stock had previously closed at $1.25.
Analysts Set New Price Targets
A number of research firms recently weighed in on NRXP. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday. HC Wainwright upped their target price on NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a “buy” rating in a report on Monday, August 5th. Finally, Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a report on Thursday, September 12th.
Read Our Latest Stock Report on NRXP
NRx Pharmaceuticals Price Performance
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.06. On average, equities research analysts expect that NRx Pharmaceuticals, Inc. will post -3.25 EPS for the current year.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
Recommended Stories
- Five stocks we like better than NRx Pharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Top Stocks Investing in 5G Technology
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is a Dividend King?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.